AllianceBernstein
CERE

AllianceBernstein’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

AllianceBernstein’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,494,341
Closed -$61.1M – 3286
2024
Q2 		$61.1M Buy
1,494,341
+321,454
+27% +$13.4M 0.02% 549
2024
Q1 		$49.6M Buy
1,172,887
+40,247
+4% +$1.69M 0.02% 603
2023
Q4 		$48M Buy
1,132,640
+1,042,100
+1,151% +$29.9M 0.02% 595
2023
Q3 		$1.98M Hold
90,540
– – ﹤0.01% 1892
2023
Q2 		$2.88M Buy
90,540
+23,340
+35% +$716K ﹤0.01% 1699
2023
Q1 		$1.64M Hold
67,200
– – ﹤0.01% 1987
2022
Q4 		$2.12M Hold
67,200
– – ﹤0.01% 1884
2022
Q3 		$1.9M Buy
67,200
+4,400
+7% +$131K ﹤0.01% 1924
2022
Q2 		$1.66M Buy
62,800
+13,400
+27% +$380K ﹤0.01% 2060
2022
Q1 		$1.73M Sell
49,400
-25,054
-34% -$732K ﹤0.01% 2173
2021
Q4 		$2.41M Buy
74,454
+16,324
+28% +$576K ﹤0.01% 2024
2021
Q3 		$1.72M Buy
58,130
+26,100
+81% +$733K ﹤0.01% 2248
2021
Q2 		$821K Buy
+32,030
New +$459K ﹤0.01% 2616

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

AllianceBernstein's CERE Position: Q3 2024 in Review

AllianceBernstein sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,494,341 shares — an estimated $61.1M sold.

AllianceBernstein first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $61.1M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • AllianceBernstein reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • AllianceBernstein sold 1,494,341 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $61.1M.
  • AllianceBernstein first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • AllianceBernstein's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $61.1M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on AllianceBernstein's 13F filing for Q3 2024, filed 14 Nov 2024.